These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33590292)

  • 41. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 44. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
    Cardle II; Cheng EL; Jensen MC; Pun SH
    Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
    Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
    Front Immunol; 2020; 11():482. PubMed ID: 32528460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
    Seimetz D; Heller K; Richter J
    Cell Med; 2019; 11():2155179018822781. PubMed ID: 32634192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.
    Nicod C; da Rocha MN; Warda W; Roussel X; Haderbache R; Seffar E; Trad R; Bouquet L; Goncalves M; Bosdure L; Laude MC; Guiot M; Ferrand C; Deschamps M
    Curr Res Transl Med; 2023; 71(2):103385. PubMed ID: 36773434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel.
    Leone G; Baldini V; Bramanti S; Crocchiolo R; Gattillo S; Ermini S; Giudice V; Ferrero I; Moscato T; Milani R; Gozzer M; Piccirillo N; Tassi C; Tassi V; Coluccia P
    Blood Transfus; 2023 Nov; 21(6):514-525. PubMed ID: 37146295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Next-Generation Manufacturing Protocols Enriching T
    Arcangeli S; Falcone L; Camisa B; De Girardi F; Biondi M; Giglio F; Ciceri F; Bonini C; Bondanza A; Casucci M
    Front Immunol; 2020; 11():1217. PubMed ID: 32636841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies.
    Lombard-Banek C; Schiel JE
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32204371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A guide to manufacturing CAR T cell therapies.
    Vormittag P; Gunn R; Ghorashian S; Veraitch FS
    Curr Opin Biotechnol; 2018 Oct; 53():164-181. PubMed ID: 29462761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [CAR T-cells: hot news in cancer therapy].
    Hrabovský Š
    Vnitr Lek; 2020; 66(7):420-424. PubMed ID: 33380120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
    Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Cells; 2020 May; 9(5):. PubMed ID: 32429189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.
    Aparicio C; Acebal C; González-Vallinas M
    Exp Hematol Oncol; 2023 Aug; 12(1):73. PubMed ID: 37605218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.